Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Global Proteomics Partnering Terms and Agreements 2010 to 2021" report has been added to ResearchAndMarkets.com's offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Proteomics Partnering Terms and Agreements 2010 to 2021 includes:
- Trends in Proteomics dealmaking in the biopharma industry since 2010
- Analysis of Proteomics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 550 Proteomics deal records and contract documents where available
- The leading antibody deals by value since 2010
- Most active Proteomics dealmakers since 2010
- The leading Proteomics partnering resources
In Global Proteomics Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Proteomics dealmaking
2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active Proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Deal terms for Proteomics partnering
2.6.1 Proteomics partnering headline values
2.6.2 Proteomics deal upfront payments
2.6.3 Proteomics deal milestone payments
2.6.4 Proteomics royalty rates
Chapter 3 - Leading Proteomics deals
3.1. Introduction
3.2. Top Proteomics deals by value
Chapter 4 - Most active Proteomics dealmakers
4.1. Introduction
4.2. Most active Proteomics dealmakers
4.3. Most active Proteomics partnering company profiles
Chapter 5 - Proteomics contracts dealmaking directory
5.1. Introduction
5.2. Proteomics contracts dealmaking directory
Chapter 6 - Proteomics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 - Proteomics deals by company A-Z
Appendix 2 - Proteomics deals by stage of development
Appendix 3 - Proteomics deals by deal type
Appendix 4 - Proteomics deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/mpv34x